Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial
Open Access
- 9 September 2026
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3339-3350
Abstract
The receptor for advanced glycation end products (RAGE), a multiligand receptor that is abundantly expressed by lung alveolar type-1 cells, amplifies and sustains the innate immune response in a variety of pulmonary disorders, including asthma and chronic obstructive pulmonary disease. Here we developed ARO-RAGE, an inhaled, lung-epithelium-targeted siRNA directed against pulmonary RAGE mRNA. Preclinical data from rat models of asthma, chronic obstructive pulmonary disease and acute lung injury, as well as mouse models for assessment of inflammatory responses, demonstrated deep and durable silencing of RAGE, limiting pulmonary inflammation. In macaques, ARO-RAGE produced dose-dependent reductions in membrane-bound RAGE levels in lung tissue and soluble RAGE (sRAGE) levels in serum; moreover, bronchoalveolar lavage showed post-dose decreases in sRAGE levels, consistent with robust silencing of lung membrane-bound RAGE. We then tested ARO-RAGE in a phase 1/2a, randomized, double-blinded, placebo-controlled trial designed to assess safety and tolerability (primary endpoint), pharmacokinetics (secondary endpoint) and pharmacodynamics (exploratory endpoint). In healthy volunteers (total n = 58, male n = 14) and in patients with asthma (total n = 19, male n = 6), inhaled ARO-RAGE was safe and well tolerated. No clinically relevant changes in chest x-ray findings, pulmonary function tests or systemic markers of inflammation were observed in the two cohorts. Plasma levels of ARO-RAGE were low, consistent with drug retention in the lung and minimal systemic bioavailability. Prolonged dose-responsive decreases in serum and bronchoalveolar lavage sRAGE levels indicated effective pulmonary target engagement. Together, these results demonstrate safe pulmonary delivery and target engagement of an inhaled, epithelial-targeted therapeutic siRNA, and support continued clinical development of ARO-RAGE. ClinicalTrials.gov registration: NCT05276570.Keywords
Funding Information
- This study was sponsored by Arrowhead Pharmaceuticals, Inc.
This publication has 36 references indexed in Scilit:
- Are We Ready for Asthma Remission as a Clinical Outcome?Chest, 2023
- The receptor for advanced glycation end products is a critical mediator of type 2 cytokine signaling in the lungsJournal of Allergy and Clinical Immunology, 2019
- sRAGE alleviates neutrophilic asthma by blocking HMGB1/RAGE signalling in airway dendritic cellsScientific Reports, 2017
- RAGE inhibition reduces acute lung injury in miceScientific Reports, 2017
- Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPDNew England Journal of Medicine, 2016
- Pulmonary receptor for advanced glycation end-products promotes asthma pathogenesis through IL-33 and accumulation of group 2 innate lymphoid cellsJournal of Allergy and Clinical Immunology, 2015
- Anti-inflammatory actions of Chemoattractant Receptor-homologous molecule expressed on Th2 by the antagonist MK-7246 in a novel rat model of Alternaria alternata elicited pulmonary inflammationEuropean Journal of Pharmacology, 2014
- Receptor for advanced glycation end products and its ligand high-mobility group box-1 mediate allergic airway sensitization and airway inflammationJournal of Allergy and Clinical Immunology, 2014
- The Receptor for Advanced Glycation End Products Is a Central Mediator of Asthma PathogenesisThe American Journal of Pathology, 2012
- Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2007